key: cord-314515-p40x3cxr
authors: NGAI, Jenny C.; KO, Fanny W.; NG, Susanna S.; TO, Kin‐Wang; TONG, Mabel; HUI, David S.
title: The long‐term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status
date: 2010-03-19
journal: Respirology
DOI: 10.1111/j.1440-1843.2010.01720.x
sha: 
doc_id: 314515
cord_uid: p40x3cxr

Background and objective: Severe acute respiratory syndrome (SARS) emerged in 2003 and its long‐term sequelae remain largely unclear. This study examined the long‐term outcome of pulmonary function, exercise capacity, health and work status among SARS survivors. Methods: A prospective cohort study of SARS patients at the Prince of Wales Hospital, Hong Kong was conducted, with serial assessments of lung function, 6MWD and 36 item Short Form General Health Survey at 3, 6, 12, 18 and 24 months after disease onset. The work status was also recorded. Results: Serial assessments were completed by 55 of the 123 (39.9%) subjects, of whom 27 were health‐care workers (HCW). The mean age of the group was 44.4 (SD 13.2) years and 19 (34.5%) were males. At 24 months, 10 (18.2%), 9 (16.4%), 6 (10.9%) and 29 (52.7%) subjects had FEV(1), FVC, TLC and DL(CO) < 80% of predicted values, respectively. The mean (SD) 6MWD increased significantly from 439.0 (89.1) m at 3 months to 460.1 (102.8) m at 6 months (P 0.016) and became steady after 6 months. However, 6MWD and 36 item Short Form General Health Survey scores were lower than the normal population throughout the study. Moreover, 29.6% of HCW and 7.1% of non‐HCW had not returned to work 2 years after illness onset. Conclusions: This 2‐year study of a selected population of SARS survivors, showed significant impairment of DL(CO), exercise capacity and health status persisted, with a more marked adverse impact among HCW.

Severe acute respiratory syndrome (SARS) is an acute severe lower respiratory illness due to infection with SARS-coronavirus. 1 3 Previous studies of survivors of acute lung injury and ARDS unrelated to SARS have shown variable degrees of residual abnormalities in pulmonary function, exercise capacity and impairment in health-related quality of life. [4] [5] [6] [7] [8] As SARS is a disease that has recently emerged, the long-term sequelae are largely unclear. Studies on the lung function outcome of SARS survivors have been reported; [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] however, the longest duration of follow up was around 3 years and small numbers of subjects were studied. 18, 19 We have previously reported the 6 month 12 and 1 year outcomes 13 from the Prince of Wales Hospital SARS patient cohort, based on the available normative lung function data collected in the 1960s. 20, 21 The objectives of the present study were to evaluate the 2-year outcome of lung function, exercise capacity, health and work status of SARS survivors based on updated normative lung function data collected in Hong Kong (HK) from 2001-2003. 22, 23 The patients came from our previously reported cohort 12, 13, 24 admitted over a period of 2 weeks from March 11 to March 25, 2003 . The diagnosis of SARS was based on the Centers for Disease Control and Prevention criteria at the time. 25 All patients in this study had subsequent laboratory confirmation of SARS. 26 The study was approved by the Ethics Committee of the Chinese University of Hong Kong.

All patients were followed up at the lung function laboratory at the Prince of Wales Hospital at the end of 3, 6, 12, 18 and 24 months after illness onset. Physical examination, pulmonary function testing, respiratory muscle strength measurement, 6-minute walk test (6MWT) and the Medical Outcomes Study 36 item Short Form General Health Survey (SF-36) 27 were performed during each visit. The health status was compared with the HK normative data collected from a random telephone survey. 28 The work status of each individual was also recorded.

Lung volumes (using the nitrogen washout method), spirometry and surface area for gas exchange were performed (Vmax System; Sensor-Medics; Yorba Linda, CA). DLCO was determined by the single breath technique using an infrared analyser. We performed spirometry (FEV1 and FVC) according to the standards of the American Thoracic Society. 29 The results of spirometry, lung volume and DLCO were compared with the normative lung function data 20, 21 (which were widely adopted as the reference data in HK before 2006) and also with the updated spirometric 22 and DLCO reference values. 23 Measurement of the maximum static inspiratory pressure (PImax) and the maximum static expiratory pressure (PEmax) were performed by a mouth pressure meter via a flanged mouthpiece. 30, 31 The 6MWD was compared against normative reference data collected from a population survey of 538 normal healthy subjects in 2004 conducted by the Coordinating Committee in Physiotherapy, Hong Kong Hospital Authority. 12, 13 

Continuous variables were compared using independent sample t-test. The lung function, 6MWD and SF-36 of patients admitted to the Intensive Care Unit (requiring intubation or not) were compared using the non-parametric Mann-Whitney U-test. Repeated measures analysis of variance (anova) was used to assess serial changes in lung function test, 6MWD and SF-36 domains. Paired sample t-test was used to test the point of plateau in 6MWD. Univariate and multivariate analysis were performed to evaluate the potential determinants of 6MWD. Pearson correlation was used to test the correlations among SF-36, lung function and 6MWD. Statistical analysis was performed using the Statistical Package for Social Science 

Of the first 138 patients hospitalized with SARS infection in March 2003, 15 (10.9%) died. 22 Among the 123 survivors, 13 (10.6%) did not attend follow up at 3 months and 6 months, 12 and a further 13 (10.6%) did not attend the 12 month assessment. Therefore, 97 patients attended all assessments including the 12 month assessment. 13 A further 14 patients (11.4%) did not attend the 18 month assessment and a further 28 (22.8%) did not attend the 24 month assessment. Overall, 55 patients (39.9%) completed all five assessments. When comparing the SARS survivors who had completed the 24 month assessment against those who had not, the former group was older with more severe disease (Table 1) .

The results of serial lung function and respiratory muscle strength testing over 24 months among SARS survivors are shown in Table 2 . The percentage of SARS survivors with lung function parameters < 80% of predicted compared with the outdated 20,21 and the updated local reference values 22, 23 and the percentages of survivors with PImax and PEmax < 80 cm H2O at 24 months are shown in Table 3 .

According to the American Thoracic Society criteria of severity of DLCO impairment, 20 (36.4%), 7 (12.7%) and 2 (3.6%) patients had mild, moderate and severe impairment, respectively, based on the updated reference values. 23 Two patients (3.6%) had obstructive spirometric abnormality; one of these had a history of COPD and pneumoconiosis and the other had a significant smoking history (25 pack-years). Three patients (5.5%) had restrictive abnormality without any comorbidity that would account for the abnormal lung function result.

The mean (SD) 6MWD increased significantly from 439.0 (89.1) m at 3 months to 460.1 (102.8) m at 6 months (P-value = 0.016) and then became steady. The mean (SD) 6MWD at 12 months, 18 months and 24 months were 464.7 (101.9) m, 466.3 (91) m and 462.6 (120) m, respectively. The P-value for trend from 3 months to 24 months was 0.45.

The SARS survivors' exercise capacity was generally lower than that of normal subjects (Table 4) . None had significant hypoxia after the 6MWT. There were no significant associations between 6MWD and any of the following: BMI, total steroid dose, length of hospital stay, admission to ICU, baseline LDH, peak LDH, baseline CRP, peak CRP, FEV1%, FVC%, DLCO%, gas transfer corrected for alveolar volume (KCO%) at 24 months post SARS.

There was impairment in all SF-36 domains (P < 0.01) at 24 months, except for role limitation due to emotional problems and mental heath for the age group 18-40 years (Fig. 1 ). Significant worsening of bodily pain was observed: 65.8 (SD, 4.01), 59.4 (SD, 3.8), 60.5 (SD, 3.7), 54.4 (SD, 3.6) and 53.8 (SD, 3.5) at 3, 6, 12, 18 and 24 months, respectively (P 0.025). The only two significant positive correlations between lung function indices and SF-36 domains were between FVC (r = 0.363, P < 0.01) and FEV1 (r = 0.3, P < 0.05) with physical functioning. However, 6MWD had significant positive correlations with all SF 36 domains except for emotional problems and mental heath. There was no significant difference in 6MWD and SF-36 domain scores between two groups at 24 months.

The percentages of patients who had returned to work over 24 months are shown in Table 5 . At 2 years, up to 29.6% of HCW but only 7.1% of non-HCW had not returned to work.

This prospective cohort study has shown that 52% of SARS survivors had persistent impairment in DLCO and that exercise capacity and health status were significantly lower than the normal controls of the same age groups at 24 months post-illness. In addition, only 78% of SARS survivors had returned to work and 29% of the HCW had not resumed duty. With more than one half of the patients having abnormal DLCO at 24 months, the data suggest impairment in the intra-alveolar diffusion pathway. Su et al. 18 reported 8/13 (61.5%) patients in Taiwan and Liu et al. 19 reported 5.4% of 39 patients in Beijing who had impairment in DLCO at 14 months and 36 months, respectively. However, these two studies were limited by very small sample sizes of highly selected patients. 18, 19 The static trend of DLCO impairment over 24 months in the current study was different from other long-term follow-up studies that showed improvement in DLCO over 1 year in Singapore, 16 and in Beijing. 17, 19 This might be explained by different methodologies in measuring DLCO among the studies. Studies of ARDS survivors unrelated to SARS have shown significant restrictive and obstructive impairment in pulmonary function tests. [32] [33] [34] Up to 76% of ARDS survivors at 5 years after recovery had impairment in DLCO. 34 It is difficult to interpret the clinical significance of the trend of KCO found, as the alveolar volume effect has not been validated in lung diseases in which lung pathology has reduced carbon monoxide (CO) uptake properties as well as alveolar volume. 35, 36 All the spirometric and lung volume parameters remained static during the study period except for a decreasing trend in the mean of the forced expiratory flow (FEF)%25-75. The percentages of patients with spirometry and lung volume impairment and restrictive abnormality at 24 months were similar to the previous 3-12 month follow-up studies on SARS survivors. 9, 11, 15 The overall pattern of lung function impairment in our study suggests small airway disease and impairment in the diffusion pathway in the SARS survivors. There were 33% and 27.8% of SARS survivors who had abnormal total CXR scores at 6 months and 12 months, respectively, in our cohort. 12, 13 The lung function impairment findings are consistent with the CT images of SARS survivors showing persistent ground glass opacity, reticular opacities and traction bronchiectasis suggesting fibrosis. [37] [38] [39] Despite the absence of bronchiolitis in the imaging of SARS patients during the acute phase, air trapping was often present and persisted in the CT scanning of SARS survivors 6 months post-infection. These findings probably reflected damage to the ciliated respiratory epithelia during the acute disease but were radiologically occult in most patients. 39 Our findings are also consistent with the histological features of SARS cases. The predominant pathological finding in SARS was diffuse alveolar damage in the early phase of the disease 24 but in the later course of disease, dense septal and alveolar fibrosis were seen. 40 A direct correlation was found between the extent of fibrosis and the duration of the illness. 41, 42 The restrictive abnormality of lung function might have also been partially due to respiratory muscle weakness, as demonstrated by persistent abnormal PEmax and decreasing trend of PImax over 24 months.

The discrepancies of the percentages of SARS survivors with abnormal lung function based on different reference values may have significant implications on compensation decisions, with more SARS patients having abnormal lung function parameters using the updated reference data 22,23 than the outdated values, 20,21 which were used by the local health authority for judging the extent of impairment.

Previous studies on SARS survivors have reported persistent impairment in exercise capacity up to 14 months post-illness. 12, 13, 15, 18 This observation was similar to that of survivors of ARDS unrelated to SARS. 4, 33 The decrease in exercise capacity has been attributed to several factors. Diffusion impairment and respiratory muscle weakness might result in exertional dyspnoea and limit performance of 6MWT. However, the reduced exercise capacity after hospital discharge in SARS survivors could not be accounted for by impairment of pulmonary function alone, 12, 13, 18, 19 whereas extra-pulmonary causes such as physical deconditioning, muscle weakness and poor motivation were contributing factors. Several reasons for muscle weakness were suggested, including viral-induced myositis at initial presentation, muscle wasting and deconditioning due to prolonged bed rest, steroid myopathy and critical illnessassociated poly-neuropathy or myopathy. 12, 13, 18, 19, 43 The persistent impairment of 6MWD was an important contributor to the reduced quality of life over 24 months. In addition to the physical impairment, mental impairment is expected as the major SARS outbreak in 2003 was a traumatic experience for the SARS survivors. 44 A striking finding was that 10 patients in our cohort had suffered from depression or post-traumatic stress disorder requiring psychiatric support. This finding was echoed by the observation that 10-18% of SARS survivors in HK had symptoms related to post-traumatic stress disorder, anxiety and depression. 44 Among SARS survivors in Canada, psychiatrist consultations accounted for the greatest numbers of health-care visits. 15 Similarly impaired health status was reported in ARDS survivors unrelated to SARS. 4, 8, 33, 34 It was reported that 66% of SARS patients in Canada had returned to full-time work 1 year after SARS. 15 Our study had higher percentages of patients returning to work at 1 and 2 years. Studies on ARDS unrelated to SARS have reported that 49% and 65% of ARDS survivors returned to full-time work at 1 year and 2 years, respectively. 4, 33 In our study, the lower percentage of HCW returning to work compared with non-HCW may be explained by the profound psychological trauma of the SARS outbreak at our hospital that involved a high percentage of HCW. 24 HCW with SARS had significantly higher stress levels, higher depression, anxiety and post-traumatic symptoms 1 year after the outbreak than non-health-care SARS survivors. 45 There are several limitations to this study. First, although this study had the largest sample size for a 2-year follow-up study, only 55 of the 123 (39.9%) survivors in the early cohort 24 completed serial assessments over 24 months. The high default rate was likely to be related to patients' efforts to reduce the SARS-associated stigma. 46 Those who had returned for follow up had more severe disease at onset and lower lung function parameters at 3 months. The results might therefore not be representative of the entire cohort. Second, 27% of SARS survivors in our cohort had medical comorbidities. This might have introduced additional impairment of exercise capacity and health status. Third, cardiopulmonary exercise testing was not performed in this study as most patients complained of generalized muscle weakness on initial follow up. 12, 13 As a result, the extrapulmonary factors contributing to the 6MWT could not be measured. Finally, respiratory muscle strength was assessed by mouth pressure in our study. Low PEmax or PImax values might be due to poor motivation and technical difficulties such as mouth leakage. 30 In summary, 2 years after SARS onset, more than 50% of this highly selected group of SARS survivors had impairment in DLCO. Their exercise capacity and health status were remarkably lower than that of the general population and 30% of HCW had not returned to work. SARS can lead to persistent mental and physical abnormalities in survivors, with a greater adverse impact on HCW. Health authorities should provide good support and follow up for these patients including HCW.

Additional Supporting Information may be found in the online version of this article: Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Aetiology: ss's postulates fulfilled for SARS virus

World Health Organization. Summary of probable SARS cases with onset of illness from 1

One-year outcomes in survivors of the acute respiratory distress syndrome

Long-term follow-up and bronchial reactivity testing in survivors of the adult respiratory distress syndrome

Pulmonary function following the adult respiratory distress syndrome

Clinical determinants of abnormalities in pulmonary functions in survivors of the adult respiratory distress syndrome

Pulmonary function and health-related quality of life in survivors of acute respiratory distress syndrome

Pulmonary function and exercise capacity in survivors of severe acute respiratory syndrome

Follow-up study on pulmonary function and lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after discharge

Six month radiological and physiological outcomes in severe acute respiratory syndrome (SARS) survivors

The impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors

The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors

Dynamic changes of serum SARScoronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge

One year outcomes and health care utilization in survivors of severe acute respiratory syndrome

1-year pulmonary function and health status in survivors of severe acute respiratory syndrome

Beijing Respiratory Experts Panel of the Medical Staff Severe Acute Respiratory Syndrome Patients. A follow-up study of the lung function and the chest CT changes in medical staff with severe acute respiratory syndrome in Beijing

Exercise capacity and pulmonary function in hospital workers recovered from severe acute respiratory syndrome

Changes in pulmonary function in SARS patients during the three-year convalescent period

A major outbreak of severe acute respiratory syndrome in Hong Kong

Severe acute respiratory syndrome (SARS) updated interim U.S. case definition

Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak

Tests of scaling assumptions and construct validity of the Chinese (HK) version of the SF 36 health survey

Population based norming of the Chinese (HK) version of the SF 36 health survey

Standardization of spirometry, 1994 update

Pulmonary function studies in healthy Chinese adults in Singapore

Clinical usefulness of the single-breath pulmonary diffusing capacity test

Updated spirometric reference values for adult Chinese in Hong Kong and implications on clinical utilization

Reference values of diffusing capacity of non-smoking Chinese in Hong Kong

Statement on respiratory muscle testing

Comparison of two different mouthpieces for the measurement of Pimax and Pemax in normal and weak subjects

Long-term assessment of lung function in survivors of severe ARDS

Two year outcomes, health care use, and costs of survivors of Acute Respiratory Distress Syndrome

Pulmonary function and health-related quality of life in a sample of long-term survivors of the acute respiratory distress syndrome

In defense of the carbon monoxide transfer coefficient KCO (TL/VA)

Standardisation of the single-breath determination of carbon monoxide uptake in the lung

Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT

Severe acute respiratory syndrome thin-section computed tomography features, temporal changes and clinical radiological correlation during the convalescent period

Radiology of severe acute respiratory syndrome (SARS): the emerging pathologic-radiologic correlates of an emerging disease

Evolution of pulmonary pathology in severe acute respiratory syndrome

Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS)

Pulmonary pathology of severe acute respiratory syndrome in Toronto

Neuromuscular disorders in severe acute respiratory syndrome

Posttraumatic stress, anxiety, and depression in survivors of severe acute respiratory syndrome (SARS)

Stress and psychological distress among SARS survivors 1 year after the outbreak

The SARS-associated stigma of SARS victims in the post-SARS era of Hong Kong

We thank the Research Fund for the Control of Infectious Diseases (Food and Health Bureau, HKSAR) for funding this study. We would like to thank the following colleagues who have offered tremendous help in this study: M Tong (nurse), PY Chan (nurse), MY Leung (nurse), and Catherine Ho (research assistant). Finally, we would like to acknowledge the Co-ordinating Committee in Physiotherapy, HK Hospital Authority, for collecting the updated normative data on 6MWD.